Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Press Release|Articles|December 2, 2024
Camber Pharmaceuticals Introduces Lidocaine HCI Injection, USP, in Single- and Multi-Dose Vials
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Lidocaine HCl Injection in single-dose and multi-dose vials with 1% and 2% concentrations.
- The product is available in various vial and pack sizes to meet diverse healthcare needs.
Featuring 1% and 2% concentrations, this versatile product is available in various vial and pack sizes to meet diverse healthcare needs.
Advertisement
Camber Pharmaceuticals is excited to introduce Lidocaine HCl Injection, USP, in Single-Dose and Multi-Dose Vials. Featuring 1% and 2% concentrations, this versatile product is available in various vial and pack sizes to meet diverse healthcare needs.
Click below to learn more:
- Single-Dose Vials:
https://www.camberpharma.com/products/lidocaine-sdv/ - Multi-Dose Vials:
https://www.camberpharma.com/products/lidocaine-mdv/
Camber Pharmaceuticals, a fully integrated pharmaceutical company, is dedicated to delivering high-quality generic medications that enhance lives through cost-effective healthcare solutions. As a subsidiary of Hetero, a global leader in active pharmaceutical ingredients (APIs) and finished dosage manufacturing based in Hyderabad, India, Camber leverages its expertise to ensure access to affordable, reliable pharmaceuticals for consumers worldwide.
Advertisement
Related to this article
AI tools in pharmacy education risk eroding critical thinking, lab competency, and patient safety if used as substitutes for foundational learning.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
National Pharmacy Technician Day: Celebrating the Backbone of Pharmacy
3
Cemdisiran’s Potential to Reduce Hospitalizations in Myasthenia Gravis
4
Supporting Patients Prescribed Opioids in the Era of “Fentanyl Free America”
5